ORCA
Online Research @ Cardiff
Browse by Current Cardiff authors
 | Up a level |
Number of items: 24.
Jones, Robert H., Casbard, Angela, Carucci, Margherita, Cox, Catrin, Butler, Rachel, Alchami, Fouad, Madden, Tracie-Ann, Bale, Catherine, Bezecny, Pavel, Joffe, Johnathan, Moon, Sarah, Twelves, Chris, Venkitaraman, Ramachandran, Waters, Simon, Foxley, Andrew and Howell, Sacha J.
2020.
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncology
21
(3)
, pp. 345-347.
10.1016/S1470-2045(19)30817-4
|
|
| Hong, David S., Concin, Nicole, Vergote, Ignace, de Bono, Johann S., Slomovitz, Brian M, Drew, Yvette, Arkenau, Hendrik-Tobias, Machiels, Jean-Pascal, Spicer, James, Jones, Robert, Forster, Martin, Cornez, Nathalie, Gennigens, Christine, Johnson, Melissa L, Thistlethwaite, Fiona C, Rangwala, Reshma A, Ghatta, Srinivas, Windfeld, Kristian, Harris, Jeffrey R, Lassen, Ulrik Niels and Coleman, Robert L. 2020. Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer. Clinical Cancer Research 26 (6) , pp. 1220-1228. 10.1158/1078-0432.CCR-19-2962 |
|
|
|
Peltola, Katriina J., Bono, Petri, Jones, Robert Hugh, Vjaters, Egils, Nykänen, Pirjo, Vuorela, Annamari, Oksala, Riikka, Pohjanjousi, Pasi, Mustonen, Mika V.J., Fizazi, Karim and Massard, Christopher
2020.
ODM-204, a novel dual Inhibitor of CYP17A1 and androgen receptor: early results from phase I dose escalation in men with castration-resistant prostate cancer.
European Urology Focus
6
(1)
, pp. 63-70.
10.1016/j.euf.2018.08.022
|
|
|
de Bono, Johann S., Concin, Nicole, Hong, David S., Thistlethwaite, Fiona C., Machiels, Jean-Pascal, Arkenau, Hendrik-Tobias, Plummer, Ruth, Jones, Robert Hugh, Nielsen, Dorte, Windfeld, Kristian, Ghatta, Srinivas, Slomovitz, Brian M., Spicer, James F., Yachnin, Jeffrey, Ang, Joo Ern, Mau-Sørensen, Paul Morten, Forster, Martin David, Collins, Dearbhaile, Dean, Emma, Rangwala, Reshma A. and Lassen, Ulrik
2019.
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
Lancet Oncology
20
(3)
, pp. 383-393.
10.1016/S1470-2045(18)30859-3
|
|
|
|
Basu, B., Krebs, M. G., Sundar, R., Wilson, R. H., Spicer, J., Jones, R., Brada, M., Talbot, D. C., Steele, N., Ingles Garces, A. H., Brugger, W., Harrington, E. A., Evans, J., Hall, E., Tovey, H., de Oliveira, F. M., Carreira, S., Swales, K., Ruddle, R., Raynaud, F. I., Purchase, B., Dawes, J. C., Parmar, M., Turner, A. J., Tunariu, N., Banerjee, S., de Bono, J. S. and Banerji, U.
2018.
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.
Annals of Oncology
29
(9)
, pp. 1918-1925.
10.1093/annonc/mdy245
|
|
|
|
Clarke, Noel, Wiechno, Pawel, Alekseev, Boris, Sala, Nuria, Jones, Robert, Kocak, Ivo, Chiuri, Vincenzo Emanuele, Jassem, Jacek, Fléchon, Aude, Redfern, Charles, Goessl, Carsten, Burgents, Joseph, Kozarski, Robert, Hodgson, Darren, Learoyd, Maria and Saad, Fred
2018.
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncology
19
(7)
, pp. 975-986.
10.1016/S1470-2045(18)30365-6
|
|
|
| Garcia Martin, Isabel, Janssen, A.B., Jones, Robert, Grimstead, Julia W., Penketh, Richard J. A., Baird, Duncan M. and John, Rosalind M. 2017. Telomere length heterogeneity in placenta revealed with high-resolution telomere length analysis. Placenta 59 , pp. 61-68. 10.1016/j.placenta.2017.09.007 |
|
|
|
Scurr, Martin, Pembroke, Tom, Bloom, Anja, Roberts, David, Thomson, Amanda, Smart, Kathryn, Bridgeman, Hayley, Adams, Richard, Brewster, Alison, Jones, Robert, Gwynne, Sarah, Blount, Daniel, Harrop, Richard, Wright, Melissa, Hills, Robert, Gallimore, Awen and Godkin, Andrew
2017.
Effect of modified vaccinia Ankara–5T4 and low-dose cyclophosphamide on antitumor immunity in metastatic colorectal cancer: A randomized clinical trial.
JAMA Oncology
3
(10)
, e172579.
10.1001/jamaoncol.2017.2579
|
|
|
| Scurr, Martin J, Pembroke, Tom, Bloom, Anja, Roberts, David J, Thomson, Amanda, Smart, Kathryn, Bridgeman, Hayley, Adams, Richard A, Brewster, Alison E, Jones, Robert, Gwynne, Sarah, Blount, Daniel, Harrop, Richard, Hills, Robert, Gallimore, Awen and Godkin, Andrew 2017. Low-dose cyclophosphamide induces anti-tumor T-cell responses which associate with survival in metastatic colorectal cancer. Clinical Cancer Research , clincanres.0895.2017. 10.1158/1078-0432.CCR-17-0895 |
|
|
|
Scurr, Martin, Pembroke, Tom, Adams, Richard, Blount, Daniel, Brewster, Alison, Gwynne, Sarah, Harrop, Richard, Jones, Robert, Hills, Robert, Gallimore, Awen and Godkin, Andrew
2017.
MVA-5T4 immunotherapy and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): An open-label, randomized phase I/II trial.
Journal of Clinical Oncology
35
(7)
, p. 154.
10.1200/JCO.2017.35.7_suppl.154
|
|
|
|
Reza, Mariana, Jones, Robert, Aspegren, John, Massard, Christophe, Mattila, Leena, Mustonen, Mika, Wollmer, Per, Trägårdh, Elin, Bondesson, Eva, Edenbrandt, Lars, Fizazi, Karim and Bjartell, Anders
2016.
Bone scan index and progression-free survival data for progressive metastatic castration-resistant prostate cancer patients who received ODM-201 in the ARADES multicentre study.
European Urology Focus
2
(5)
, pp. 547-552.
10.1016/j.euf.2016.01.005
|
|
|
|
Fizazi, Karim, Massard, Christophe, Bono, Petri, Jones, Robert, Kataja, Vesa, James, Nicholas, Garcia, Jorge A., Protheroe, Andrew, Tammela, Teuvo L., Elliott, Tony, Mattila, Leena, Aspegren, John, Vuorela, Annamari, Langmuir, Peter and Mustonen, Mika
2014.
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Lancet Oncology
15
(9)
, pp. 975-985.
10.1016/S1470-2045(14)70240-2
|
|
|
| Greenow, K. R., Clarke, A. R., Williams, G. T. and Jones, R. 2014. Wnt-driven intestinal tumourigenesis is suppressed by Chk1 deficiency but enhanced by conditional haploinsufficiency. Oncogene 33 , pp. 4089-4096. 10.1038/onc.2013.371 |
|
| Greenow, Kirsty Rhian, Clarke, Alan Richard and Jones, Robert H. 2009. Chk1 deficiency in the mouse small intestine results in p53-independent crypt death and subsequent intestinal compensation. Oncogene 28 (11) , pp. 1443-1453. 10.1038/onc.2008.482 |
|
|
| Robinson, H. M. R., Jones, Robert H., Walker, M., Zachos, G., Brown, R., Cassidy, J. and Gillespie, D. A. F. 2006. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 25 (39) , pp. 5359-5369. 10.1038/sj.onc.1209532 |
|
|
| Jones, Robert H., Reubi, Jean-Claude, Millan, David and Vasey, Paul 2004. Octreotide: an active agent in epithelial ovarian carcinoma? The Lancet Oncology 5 (4) , pp. 251-253. 10.1016/S1470-2045(04)01430-5 |
|
|
| Jones, Robert H., Goldstein, David, Kurtovic, Jelica, Keogh, Gregory and Riordan, Stephen M. 2003. Compression of liver parenchyma by a malignant hepatic cyst a previously unreported manifestation of metastatic gastric cancer [Letter]. The American Journal of Gastroenterology 98 (5) , pp. 1211-1213. 10.1016/S0002-9270(03)00170-9 |
|
|
| Jones, Robert H., Ryan, Mary and Friedlander, Michael 2003. Carboplatin hypersensitivity reactions: re-treatment with cisplatin desensitisation. Gynecologic Oncology 89 (1) , pp. 112-115. 10.1016/S0090-8258(03)00066-0 |
|
|
| Jones, Robert H. and Vasey, P. A. 2003. New directions in testicular cancer; molecular determinants of oncogenesis and treatment success. European Journal of Cancer 39 (2) , pp. 147-156. 10.1016/S0959-8049(02)00612-3 |
|
|
| Jones, Robert H. and Vasey, Paul A 2003. Part II: Testicular cancer - management of advanced disease. The Lancet Oncology 4 (12) , pp. 738-747. 10.1016/S1470-2045(03)01279-8 |
|
|
| Twelves, Chris and Jones, Robert H. 2001. Oral uracil-tegafur: an alternative to intravenous 5-fluorouracil? Expert Opinion on Pharmacotherapy 2 (9) , pp. 1495-1505. 10.1517/14656566.2.9.1495 |
|
|
| Millar, J. B., McGowan, C. H., Lenaers, G., Jones, Robert and Russell, P. 1990. p80cdc25 mitotic inducer is the tyrosine phosphatase that activates p34cdc2 kinase in fission yeast. Embo Journal 10 (13) , pp. 5610-5621. |
|
|
| Jones, Robert and Jones, N. C. 1989. Mammalian cAMP-responsive element can activate transcription in yeast and binds a yeast factor(s) that resembles the mammalian transcription factor ATF. Proceedings of the National Academy of Sciences of the United States of America (PNAS) ISSN 1091-6490 86 (7) , pp. 2176-2180. |
|
|
| Jones, Robert, Moreno, Sergio, Nurse, Paul and Jones, Nicholas C. 1988. Expression of the SV40 promoter in fission yeast: identification and characterization of an AP-1-like factor. Cell 53 (4) , pp. 659-667. 10.1016/0092-8674(88)90581-8 |
|
|
Cardiff University Information Services